Abstract: The present invention relates to novel aminoglycoside antibiotics, a process for producing the same, and pharmaceutical use thereof. More specifically, the present invention relates to compounds represented by formula (I), a process for producing the same, and use of the same as antimicrobial agents. wherein R represents amino or hydroxyl.

Abstract: A new metallo-?-lactamase inhibitor which acts as a medicament for inhibiting the inactivation of ?-lactam antibiotics and recovering anti-bacterial activities is disclosed. The maleic acid derivatives having the general formula (I) have metallo-?-lactamase inhibiting activities. It is possible to recover the anti-bacterial activities of ?-lactam antibiotics against metallo-?-lactamase producing bacteria by combining the compound of the general formula (I) with ?-lactam antibiotics.

Abstract: Provided is a novel antibody having an excellent antibacterial activity against P. aeruginosa. By using plasmablasts obtained from cystic fibrosis patients with chronic P. aeruginosa pulmonary infection as starting materials, antibodies which bind to LPS of a P. aeruginosa strain of serotype I and which have excellent antibacterial activities in vitro and in vivo were successfully obtained.

Abstract: 2-Ethenylthio-type carbapenem derivatives of formula (I) or pharmaceutically acceptable salts thereof are provided. The compounds according to the present invention have potent antimicrobial activity and a wide antimicrobial spectrum against pneumococci including penicillin resistant Streptococcus pneumoniae (PRSP), Haemophilus influenzae including ?-lactamase-negative, ampicillin-resistant Haemophilus influenzae (BLNAR), and Moraxella (Branhamella) catarrhalis.

Abstract: An objective of the present invention is to provide agricultural and horticultural disease control agents that have potent control effect against plant diseases and, at the same time, have high photostability. The agricultural and horticultural disease control agents comprise a novel substance analogous to MK8383 as an active ingredient.

Abstract: [Object]: To provide a compound having a novel structure effective against Hemophilus influenzae and erythromycin resistant bacteria (for example, resistant pneumococci and streptococci) as well as against conventional erythromycin sensitive bacteria. [Solution]: A novel 10a-azalide compound represented by the formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof, or an intermediate for the preparation of the same. The compound of the present invention has superior antibacterial activity against Hemophilus influenzae, erythromycin resistant pneumococci and the like, and therefore, the compound can be used as a therapeutic agent of infectious diseases.

Abstract: A new metallo-?-lactamase inhibitor which acts as a medicament for inhibiting the inactivation of ?-lactam antibiotics and recovering anti-bacterial activities is disclosed. The maleic acid derivatives having the general formula (I) have metallo-?-lactamase inhibiting activities. It is possible to recover the anti-bacterial activities of ?-lactam antibiotics against metallo-?-lactamase producing bacteria by combining the compound of the general formula (I) with ?-lactam antibiotics.

Abstract: An object of the present invention is to provide a protein or peptide antigen and an antibody against it, for use in the diagnosis, prevention, or treatment of diseases associated with Pseudomonas aeruginosa. According to the present invention, there is provided a protein or peptide derived from Pseudomonas aeruginosa outer membrane protein PA0427 and an antibody against it, for use in the diagnosis, prevention, or treatment of diseases associated with Pseudomonas aeruginosa.

Abstract: Disclosed are whey protein-containing granules which can dissolve a whey protein into water without forming insoluble lumps thereby making a solution containing the dissolved whey protein clear without turbidity, and a method for producing the same. The whey protein-containing granules are composed of a polyglycerin fatty acid ester having HLB of 13 to 18 and containing lauric acid as a constituent fatty acid. As the polyglycerin fatty acid ester, for example, monolauric acid decaglycerin ester or monolauric acid pentaglycerin ester may be used.

Abstract: An antibacterial agent having high antibacterial activity against Mycobacterium avium subsp. paratuberculosis is provided. Specifically, the antibacterial agent of the present invention having high antibacterial activity against Mycobacterium avium subsp. paratuberculosis is a caprazamycin derivative represented, for example, by the following general formula (II): wherein Me is a methyl group; and R1 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, a cycloalkyl group having 5 to 12 carbon atoms, or a phenyl group substituted at the para-position with a straight chain alkyl group having 1 to 14 carbon atoms, a straight chain alkoxy group having 1 to 9 carbon atoms or a cycloalkyl group having 5 to 12 carbon atoms.

Abstract: A midecamycin hyper producing strain having improved productivity of midecamycin which is a member of macrolide antibiotics, and a method for producing midecamycins using the strain are provided. The midecamycin producing actinomycetes comprises a midecamycin biosynthesis gene or a homologue thereof, wherein at least one module in a polyketide synthase gene of a midecamycin biosynthesis gene or partial sequences of the at least one module, is substituted so as to encode the corresponding amino acid sequences of the other module.

Abstract: A novel 10a-azalide compound crosslinked at the 10a- and 12-positions, which is represented by the following formula, and is effective on even Hemophilus influenzae, or erythromycin resistant bacteria (e.g., resistant pneumococci and streptococci).

Abstract: A method for efficiently producing 4-(hydroxymethylphosphinyl)-2-oxobutanoic acid, useful as a production intermediate of herbicide L-AMPB. The method comprises using a compound represented by the below formula (4): (4) where R1 represents a C1-4 alkyl group, arylmethyl group, or substituted arylmethyl group.

Abstract: ?-Amyrin, a precursor in biosynthesis of soyasapogenol B, is biosynthesized by cyclization of 2,3-oxidosqualene which is generated by the mevalonate pathway, and soyasapogenol B is biosynthesized by two hydroxylations of ?-amyrin. However, a gene of 22-hydroxylase involved in the sequence of reactions has not been identified. The present inventors identified a gene encoding the hydroxylase for oleanene triterpenes at C-22, and found that oleanene triterpenes could be hydroxylated at C-22 by co-expressing this gene together with one or more specific genes. Further, the present inventors found that soyasapogenol B could be efficiently produced in large quantities by co-expressing this gene for 22-hydroxylase with a gene for 24-hydroxylase.

Abstract: [Technical Problem] To provide a novel imino derivative capable of being an insecticide compound having excellent characteristics such as sustained effects and broad spectrum. [Solution to Problem] To provide an imino derivative represented by Formula (1). wherein “Ar” denotes a heterocyclic group which may have a substituent on the ring; “X” denotes a sulfur atom or CH2, NR; “R” denotes a hydrogen atom or an alkyl group; “Y” is selected from COR1 or CONR3R4, CONHCOR5, CO2R9; and each of “R1”, “R3”, “R4”, “R5”, and “R9” denotes a hydrogen atom or a certain substituent.

Abstract: The present invention relates to a process for preparing compositions of high concentrations of omega-3 fatty acids from krill. Furthermore, the invention relates to a composition comprising high concentrations of omega-3 fatty acids, and a lipid fraction from krill comprising high amounts of the fatty acids with chain length C14 and C 16.

Abstract: An object of the present invention is to provide an adhesion-preventing material which is capable of effectively preventing the surfaces of organs from adhesion, and which can be absorbed in the body with high safety and produced with ease and has high practical utility, as well as to a process for preventing adhesion by using the adhesion-preventing material. The present invention provides (1) an adhesion-preventing material comprising a crosslinked water absorbent poly-?-glutamic acid as an effective ingredient; (2) the adhesion-preventing material described above, wherein the crosslinked water absorbent poly-?-glutamic acid is in the form of powder having a water absorption coefficient in the range of 800-2000; (3) a process for preventing organ from adhesion, comprising a step of bringing the adhesion-preventing material described above into contact with the surface of a local organ; and (4) the process for preventing adhesion described above, wherein the surface of the local organ is in wet state.

Abstract: A sialogogue characterized by comprising polyglutamic acid or its salt. This sialogogue is blended into an oral composition and a food product. This sialogogue is capable of rendering the oral mucosa pleasant even in the case of severe xerostomia.

Abstract: The present invention provides a pharmaceutical composition for use in the prophylaxis or treatment of allergic ophthalmic diseases or allergic nasal diseases, which comprises 7,8-dimethoxy-4(5H),10-dioxo-1H-1,2,3-triazolo[4,5-c][1]benzazepine, 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7,8-dimethoxy-4(5H),10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine or a pharmaceutically acceptable salt thereof. The pharmaceutical composition according to the present invention has few side effects, exerts strong prophylactic and therapeutic effects in the late phase exhibiting pharmaceutical resistance to conventional instillations, and can be used appropriately for topical applications.

Abstract: The present invention provides a composition for beverage use comprising an acidic soluble protein, and one or two or more powdery or granular salts selected from the group consisting of alkali metal salts of organic acids and water-soluble basic salts, wherein at least the acidic soluble protein is granulated. Furthermore, the present invention provides a process for producing a composition for beverage use containing an acidic soluble protein, comprising: adding to the acidic soluble protein one or two or more powdery or granular salts selected from alkali metal salts of organic acids and water-soluble basic salts in a proportion of 0.01 to 10 parts by weight with respect to 100 parts by weight of the acidic soluble protein, and subjecting at least the acidic soluble protein to granulation. In the composition for beverage use, the formation of undissolved lumps when the composition is dissolved in water is suppressed.